Therefore, aberrant activation and nuclear accumulation of pSTAT3 are potentially critical for imatinib resistance in KLC2-MT CML cells (Fig. 6). The gene discussed is KLC2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.